Delivery Order SPE2DR25D1053-SPE2DR26FV205
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 5, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in 120 mL quantities, with a ceiling value of $1,862.76 and a firm fixed price contract type. This delivery order represents a non-set-aside, competitively awarded procurement and is scheduled for completion by November 6, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 28, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120ml quantities, valued at $1,526.88. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of December 1, 2025. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania facility, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity, with a ceiling value of $1,809.72. This is a firm fixed-price delivery order with an ultimate completion date of October 24, 2025, and represents a non-set-aside competitive award. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) valued at $1,740.04 under a firm fixed-price contract type. This delivery order, which has an ultimate completion date of July 31, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity, valued at $1,807.02. This is a firm fixed-price delivery order with no set-aside designation, indicating it was awarded through open competition. The order is scheduled for completion by June 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 60 ml quantity, with a ceiling value of $2,365.56 and an ultimate completion date of September 10, 2025. The contract utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award to this major pharmaceutical distributor. The place of performance is AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,721.55 for Quillivant XR 25 mg/5 ml suspension (150 ml) with a firm fixed price structure. The award was made on December 5, 2025, with an ultimate completion date of December 8, 2025. This non-set-aside contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its headquarters as a major pharmaceutical distributor serving...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,293.41 on November 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 150 ml quantities. This is a firm fixed-price delivery order with an ultimate completion date of November 26, 2025, and represents a non-competitive, non-set-aside award. The product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate office. This delivery order is a child...
- The Defense Logistics Agency awarded a delivery order valued at $1,043.22 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml), with an ultimate completion date of November 5, 2025. This firm fixed price delivery order, awarded on November 4, 2025, represents a competitively awarded contract with no set-aside designation. The product will be performed at the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, with a ceiling value of $2,502.31 and a firm fixed price structure. The award, issued on December 29, 2025, with an ultimate completion date of December 30, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FV205Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 5, 2026, for the supply of Quillivant XR 25 mg/5 ml suspension in 150ml quantities, with a ceiling value of $5,042.70 and a firm fixed price contract type. This award was not set aside for small business or other designated groups and represents a competitively awarded delivery order under AmerisourceBergen's existing contract vehicle. The place of performance is identified as Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that provides comprehensive pharmaceutical and medical supply support to military healthcare programs worldwide. AmerisourceBergen is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.0k | 1/4/26 |